ClinicalTrials.gg
CompletedNCT07553663Updated Oct 16, 2026

Evaluating the Pharmacokinetics and Safety of Miricorilant

A Phase 1 interventional study of Miricorilant in Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), sponsored by Corcept Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
394th of 460
14 · median 56
Started
2026
with 7 others
Phase 1
79 of 547
6 open now
Registered
545th of 547
by date
Lead sponsor
8 of 547
Corcept Therapeutics

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 394th largest by enrollment of the 460 interventional ones that give a count, is one of 8 that started in 2026, is one of 79 in phase 1, and was the 545th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Read the detailed description

Approximately 15 patients who are eligible for participation in the study will be administered a single dose of 60 mg of miricorilant. The maximum expected duration of a patient's participation is 56 days (up to 28 days of screening, followed by single-dose administration and 4 days of observation, and then 24 days of follow-up).

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
  • Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
  • Non-alcoholic Fatty Liver Disease (NAFLD)

Keywords

  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic dysfunction-Associated Steatohepatitis (MASH)
  • Metabolic dysfunction-Associated Steatosis Liver Disease (MASLD)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of presumed MASH with either FibroScan liver stiffness measurement ≥ 8 kPa and controlled attenuation parameter (CAP) ≥ 280 dB/m OR historical within 12 months of screening that meets the following criteria:

    1. Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) ≥ 3 with at least ≥ 1 point in any two subcomponents of steatosis, inflammation, and ballooning, and a Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) fibrosis score of F1 OR
    2. NAS ≥ 2 with at least ≥ 1 point in any two subcomponents of steatosis, inflammation, and ballooning, and a NASH CRN fibrosis score of F2 or 3.
  • (AST) > 17 U/L for women and AST > 20 U/L for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of Screening.
  • Presence of at least 1 of the following metabolic conditions that increase the risk of MASH:

    1. Diagnosis of type 2 diabetes OR
    2. Presence of 2 or more components of metabolic syndrome:

      • Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or treatment for elevated blood glucose
      • Systolic blood pressure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg, or treatment for hypertension
      • Serum triglycerides ≥ 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides
      • Serum high-density lipoprotein (HDL) cholesterol \< 40 mg/dL (1 mmol/L) in men and \< 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL
      • Overweight or obese ( [BMI] ≥ 25 kg/m2 [BMI ≥ 23 kg/m2 in Asians]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm [35.4 in]; women ≥ 80 cm [31.5 in] in Asians).

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, planning to become pregnant, or are lactating.
  • Have a \< 18 kg/m2 or > 45 kg/m2.
  • Have significant alcohol consumption of more than 20 g per day for women and 30 g per day for men within 1 year prior to screening or score of ≥8 on AUDIT questionnaire
  • Have had liver transplantation or plan to have liver transplantation during the study.
  • Have type 1 diabetes.
  • Have poorly controlled type 2 diabetes with a (HbA1c)

    • 9.5%.
  • Have any other chronic liver disease
  • History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver evaluation
  • Have hepatic decompensation

Other exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Miricorilant 60mg

    Patients who meet the entry criteria for study CORT118335-863 will be administered a single dose of 60 mg miricorilant.

    Drug: Miricorilant

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of miricorilant PK parameters

    Time to maximum concentration (Tmax)

    Time frame: Day 1- Day 4

  2. Assessment of miricorilant PK parameters

    Maximum concentration over the dosing interval (Cmax)

    Time frame: Day 1 - Day 4

  3. Assessment of miricorilant PK parameters

    Concentration at 24 hours post-dose (C24)

    Time frame: Day 1 - Day 4

  4. Assessment of miricorilant PK parameters

    Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC(0-last))

    Time frame: Day 1 - Day 4

  5. Assessment of miricorilant PK parameters

    Area under the concentration-time curve from time 0 to time 24 hours post-dose (AUC(0-24))

    Time frame: Day 1 - Day 4

  6. Assessment of miricorilant PK parameters

    Area under the concentration-time curve from time zero extrapolated to infinity (AUC(0-inf)),

    Time frame: Day 1 - Day 4

  7. Assessment of miricorilant PK parameters

    Partial areas under the concentration-time curve from time 0 to time 6 hours and/or 8 hours post-dose (AUC(0-6), AUC(0-8))

    Time frame: Day 1 - Day 4

  8. Assessment of miricorilant PK parameters

    Apparent terminal elimination half-life (T1/2)

    Time frame: Day 1 - Day 4

Secondary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), clinical laboratory evaluations, (hematology, clinical chemistry, urinalysis), 12-lead electrocardiograms (ECGs), vital sign measurements and physical examinations.

    Time frame: Day 1- Day 28

07

Study locations

1 site
  • Site# 433
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Sep 2026, 4 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 28, 2026
StartActual
Apr 30, 2026
Primary completionActual
Sep 22, 2026was Oct 2026
CompletionActual
Sep 22, 2026was Oct 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Primary completion
Oct 30, 2026→Sep 22, 2026 (actual)
Oct 16, 2026
Study completion
Oct 30, 2026→Sep 22, 2026 (actual)
Oct 16, 2026
Enrollment
15 (estimated)→14 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    Primary completion Oct 30, 2026→Sep 22, 2026 (now actual)
    Study completion Oct 30, 2026→Sep 22, 2026 (now actual)
    Enrollment 15 (estimated)→14 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07553663
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Apr 30, 2026
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Oct 16, 2026

Study contacts

Aprille Espinueva, PharmD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion